Stapled Peptide Inhibitors of NEMO for NF-kB Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide inhibitors of NEMO, such as UBI, face challenges with thermal stability, cell penetration, and serum stability, and are less potent in inhibiting the NF-κB signaling pathway, particularly in cancer cells with hyperactivation.
Innovation Solution
Design and synthesis of stapled peptides with a macrocycle-forming linker that are at least 60% identical to the UBI sequence, enhancing thermal stability, α-helicity, and binding affinity to the CC2-LZ domain of NEMO, and capable of cell penetration without the need for additional cell-penetrating peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional peptide inhibitors like UBI are used, then binding affinity to NEMO is achieved, but thermal stability and serum stability are insufficient
Solution Approach 1:
The patent modifies the peptide sequence parameters by incorporating stapled residues (e.g., Aib, 2-Aib, 4-MeAib) at specific positions to alter the conformational parameters and stability characteristics. This changes the physical-chemical parameters of the peptide to enhance thermal and serum stability while maintaining binding affinity.
Solution Approach 2:
The patent creates composite peptide structures by combining conventional peptide sequences with stapled residues and macrocycle-forming linkers. This composite approach integrates multiple functional elements: the parent peptide provides binding affinity while the stapled segments provide structural stability and resistance to degradation.
2Reliability
If conventional peptide inhibitors are used, then NF-κB inhibition activity is achieved, but cell penetration capability is insufficient
Solution Approach 1:
The patent modifies the peptide's physical-chemical parameters by introducing hydrophobic stapled residues and macrocycle linkers that alter membrane permeability. These parameter changes enable the peptide to passively penetrate cell membranes more effectively while retaining its NF-κB inhibition function.
3Reliability
If conventional peptide inhibitors are used, then binding affinity to CC2-LZ domain is achieved, but thermal stability is insufficient
Solution Approach 1:
The patent constructs composite peptide structures where stapled residues and macrocycle linkers are integrated into the parent peptide sequence. This composite architecture provides both high binding affinity (through the parent peptide's interaction with CC2-LZ) and enhanced thermal stability (through the rigid stapled segments and macrocycles).
Solution Approach 2:
The patent changes the conformational and structural parameters of the peptide by incorporating stapled residues that lock the peptide into a stable α-helical structure. This parameter modification increases the energy barrier for thermal denaturation while preserving the binding interface's affinity for the CC2-LZ domain.
4Reliability
If IKK kinase inhibitors are used, then NF-κB signaling is inhibited, but toxicity side effects increase
Solution Approach 1:
The patent extracts the essential inhibitory function from the IKK kinase complex and targets it directly at the NEMO ubiquitin binding domain. By taking out the inhibition action from the kinase component and applying it at the ubiquitin binding interface, the patent achieves NF-κB inhibition with reduced off-target toxicity effects associated with IKK kinase inhibitors.
Data Source
AI summary
The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor κB (NF-κB) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.